کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3988327 1601478 2007 7 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Correlation between molecular metastases in sentinel lymph nodes of breast cancer patients and St Gallen risk category
چکیده انگلیسی

AimsTo evaluate the clinical significance of tumour metastases detected using real-time reverse transcription-PCR (RT–PCR) in sentinel lymph nodes (SLN) of breast cancer patients.MethodsSixty-seven patients with T1–T2 primary breast cancer were included in a prospective study. SLN were analysed for the presence of metastatic tumour cells using standard histopathology staining, immunochemistry (IHC) and multimarker real-time RT–PCR assay for mammaglobin (MMG), carcinoembryonic antigen (CEA) and cytokeratin-19 (CK19) mRNA expression. Correlations between molecular metastases and traditional clinicopathological prognostic factors, including St Gallen risk categories were studied.ResultsOf the 67 patients, 15 (22.3%) had one or more pathology-positive SLN. Five (9.6%) pathology-negative SLN were positive by IHC and 19 (36.5%) by RT–PCR. Of note, RT–PCR analysis was also positive in all cases with pathology- or IHC-positive SLN. MMG was the most informative tumour marker in the panel. Molecularly detected metastases were significantly associated with intermediate St Gallen risk category (p = 0.023).ConclusionMolecular staging of SLN using real-time RT–PCR for early breast cancer could serve as a useful complement to standard clinicopathological risk factors. Studies with long-term follow-up are necessary to define the impact of molecular metastases on disease free survival and overall survival.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Surgical Oncology (EJSO) - Volume 33, Issue 1, February 2007, Pages 16–22
نویسندگان
, , , , , , , , , , ,